The seed capital will help UAB-founded TriAltus Bioscience commercialise its protein purification materials, which are already being used by research clients in the US, Brazil and EU.

TriAltus Bioscience, a US-based protein purification technology spinout of University of Alabama at Birmingham (UAB), has raised $1.6m in a seed round featuring unnamed angel investors.
Founded in 2017, TriAltus Bioscience is commercialising protein purification materials that utilise a technique called CL-4 affinity purification to quickly isolate proteins at a higher purity than alternative methods.
The technology is designed for scientific research applications such as the production of therapeutic proteins. In addition to the purification technology, TriAltus also…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?